Caribou Biosciences Inc. (NASDAQ: CRBU) stock fell -10.32% on Monday to $5.26 against a previous-day closing price of $5.86. With 2.06 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.59 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.75 whereas the lowest price it dropped to was $5.25. The 52-week range on CRBU shows that it touched its highest point at $12.40 and its lowest point at $3.96 during that stretch. It currently has a 1-year price target of $23.86. Beta for the stock currently stands at 1.97.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRBU was down-trending over the past week, with a drop of -17.76%, but this was down by -14.13% over a month. Three-month performance surged to 21.08% while six-month performance rose 5.95%. The stock lost -58.91% in the past year, while it has lost -16.32% so far this year. A look at the trailing 12-month EPS for CRBU yields -1.82 with Next year EPS estimates of -1.86. For the next quarter, that number is -0.42. This implies an EPS growth rate of -47.20% for this year and -10.70% for next year.
Float and Shares Shorts:
At present, 88.28 million CRBU shares are outstanding with a float of 77.29 million shares on hand for trading. On Aug 30, 2023, short shares totaled 6.79 million, which was 7.69% higher than short shares on Jul 30, 2023. In addition to Dr. Rachel E. Haurwitz Ph.D. as the firm’s Co-Founder, CEO, Pres & Director, Ms. Ruhi A. Khan M.B.A. serves as its Chief Bus. Officer.
Institutional Ownership:
Through their ownership of 59.40% of CRBU’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.89% of CRBU, in contrast to 36.14% held by mutual funds. Shares owned by individuals account for 17.47%. As the largest shareholder in CRBU with 6.31% of the stake, PFM Health Sciences LP holds 5,570,869 shares worth 5,570,869. A second-largest stockholder of CRBU, BlackRock Fund Advisors, holds 4,138,205 shares, controlling over 4.69% of the firm’s shares. Point72 Asset Management LP is the third largest shareholder in CRBU, holding 4,085,544 shares or 4.63% stake. With a 2.28% stake in CRBU, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,009,575 shares are owned by the mutual fund manager. The Pictet – Biotech, which owns about 2.04% of CRBU stock, is the second-largest Mutual Fund holder. It holds 1,803,332 shares valued at 10.62 million. iShares Russell 2000 ETF holds 1.48% of the stake in CRBU, owning 1,302,029 shares worth 7.67 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, CRBU reported revenue of $4.19M and operating income of -$28.43M. The EBITDA in the recently reported quarter was -$28.06M and diluted EPS was -$0.44.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRBU since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRBU analysts setting a high price target of $30.00 and a low target of $19.00, the average target price over the next 12 months is $23.86. Based on these targets, CRBU could surge 470.34% to reach the target high and rise by 261.22% to reach the target low. Reaching the average price target will result in a growth of 353.61% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded CRBU stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 47,079 while 15,627 shares were sold.
